CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

FierceBiotech
Original article

{"a":[{"_":"Tarsus pays $450M for Alkeus and its phase 3-stage retinal disease drug","$":{"href":"/biotech/tarsus-stakes-450m-alkeus-phase-3-retinal-disease-drug","hreflang":"en"}}]}

Positive
AI Analysis

Summary

Tarsus Pharmaceuticals announced the acquisition of Alkeus Pharmaceuticals for $450 million to obtain a phase 3-stage retinal disease therapy with blockbuster potential.

Clinical Trial Data

Phase

Phase 3

Importance:7/10
Sentiment:
0.60
M&APhase 3retinal diseaseblockbuster potential
Related Companies

Read the original article

Published by FierceBiotech on August 6, 2026 10:07 AM

Read Original